Masayo Iwasa

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Nlrp Inflammasome

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)
Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)
Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)
Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)
Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)
Hisashi Kato, Kaori Iwashita, Masayo Iwasa, Sayaka Kato, Hajime Yamakage, Takayoshi Suganami, Masashi Tanaka, Noriko Satoh-Asahara
Imeglimin Exhibits Novel Anti-Inflammatory Effects on High-Glucose-Stimulated Mouse Microglia through ULK1-Mediated Suppression of the TXNIP-NLRP3 Axis. Cells 13 (3) (2024)